Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App





Fapon Highlights Local Manufacturing Solutions and Recombinant QC Materials

By LabMedica International staff writers
Posted on 16 Nov 2026

Fapon (Dongguan, China) is showcasing its local manufacturing solutions and comprehensive in vitro diagnostics (IVD) portfolio at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. More...

At Hall 3, Stand D95, the company is highlighting technologies and services designed to support localized diagnostic production, including integrated IVD solutions, recombinant quality control (QC) materials, and calibrator raw materials. These offerings aim to help diagnostic manufacturers strengthen local production capabilities and maintain reliable material supplies.

Local Manufacturing Solutions

Among the featured offerings are Fapon's Local Manufacturing Solutions, covering chemiluminescence immunoassays (CLIA), ELISA, clinical biochemistry, point-of-care testing (POCT), and molecular diagnostics. The solutions provide end-to-end technology transfer and localization support, including core raw materials, bulk reagents, custom development, manufacturing, and registration assistance. Through these services, Fapon helps diagnostic manufacturers establish or expand local production capabilities, from assay development to commercialization.

One-Stop IVD solutions

Fapon is also presenting its integrated IVD solutions, which combine diagnostic raw materials, reagent services, and open-system instruments. The company's capabilities encompass antibody discovery, process development, reagent formulation, and customization. Among the highlighted applications is a blood-based Alzheimer's disease testing solution, providing raw materials and bulk reagents for biomarkers including phosphorylated tau 217 (p-tau217), p-tau181, amyloid beta 40 (Aβ40), Aβ42, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL). These materials support manufacturers developing blood-based assays for Alzheimer's disease.

Recombinant quality control (QC) and calibrator raw materials

Another key highlight is Fapon's recombinant QC and calibrator raw materials, developed to improve consistency and reduce supply variability associated with naturally sourced materials. Using recombinant expression technology, the materials are designed to provide high lot-to-lot consistency while minimizing biosafety risks. In application evaluations, rheumatoid factor (RF) dilution linearity demonstrated an R² value of 0.9989, while clinical comparison testing showed an R² value of 0.9924. The portfolio covers diagnostic markers including RF, C-reactive protein (CRP), creatine kinase-MB (CK-MB), HIV/HIV-p24, hepatitis B virus (HBV), and ToRCH, supporting clinical biochemistry, CLIA, ELISA, and POCT applications.

Fapon also offers flexible production volumes of 0.8, 2, 6, and 60 liters, using vessels of up to 200 liters, with batch sizes tailored to customer demand. Quarterly production cycles, available inventory, and overseas warehouses support material availability and distribution. Together, these capabilities reflect Fapon's focus on supporting diagnostic manufacturers through localized production, integrated development services, and reliable IVD raw material supply.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researchers developed a blood test that accurately distinguishes early-stage breast cancer from healthy controls and may outperform tissue biopsy in predicting recurrence risk (Image Credit: Adobe Stock)

Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk

Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.